Post by Merck Healthcare

721,644 followers

Some patients will go their entire lives without ever meeting someone else with the same diagnosis. That’s the reality for many people living with rare tumors: isolating, chronic and potentially disfiguring conditions that can change identity and take over one’s life. During ASCO 2026, our team continued to build our footprint in this space with urgency and scientific rigor, with a clear commitment to standing alongside scientific and patient advocacy communities on a journey toward better lives for patients with conditions like desmoid tumors, NF1-PN, and TGCT. Watch our Global Head of Rare Tumors, Francois Feig and the Head of Global Commercial Strategy Andrew Paterson, share how we are showing up #AsOneForPatients, and what drives us forward in rare tumors. #ASCO26

Post content

Video Content